

# **Certificate of Analysis**

Print Date: Mar 23rd 2021

www.tocris.com

Product Name: FTBMT Catalog No.: 6784 Batch No.: 1

CAS Number: 1358575-02-6

IUPAC Name: 4-[3-[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]-5-methyl-1*H*-1,2,4-triazol-1-yl]-2-methylbenzamide

## 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:**  $C_{19}H_{16}F_4N_4O$ 

**Batch Molecular Weight:** 392.35 **Physical Appearance:** White solid

Solubility: DMSO to 100 mM

ethanol to 50 mM

Storage: Store at -20°C

**Batch Molecular Structure:** 

#### 2. ANALYTICAL DATA

**HPLC:** Shows 99.4% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 58.16 4.11 14.28 Found 57.92 4.14 14.14



# **Product Information**

Print Date: Mar 23rd 2021

www.tocris.com

Product Name: FTBMT Catalog No.: 6784 Batch No.: 1

CAS Number: 1358575-02-6

IUPAC Name: 4-[3-[[3-Fluoro-5-(trifluoromethyl)phenyl]methyl]-5-methyl-1*H*-1,2,4-triazol-1-yl]-2-methylbenzamide

#### **Description:**

FTBMT (also known as TP 024) is a potent and selective GPR52 agonist (EC $_{50}$  = 75 nM, E $_{max}$  = 122%), which is selective for GPR52 over a panel of 98 targets including D $_{1}$ , D $_{2}$ , AMPA and NMDA. FTBMT suppresses methamphetamine-induced hyperlocomotion in mice, and inhibits MK-801-induced hyperactivity (model for acute psychosis), without causing catalepsy in mice. This compound is orally bioavailable and brain penetrant.

### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O Batch Molecular Weight: 392.35 Physical Appearance: White solid

**Minimum Purity**: ≥98%

# **Batch Molecular Structure:**

Storage: Store at -20°C

# Solubility & Usage Info:

DMSO to 100 mM ethanol to 50 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

**Nishiyama** *et al* (2017) FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia. J.Pharmacol.Exp.Ther. **363** 253. PMID: 28851764.

**Tokumaru** *et al* (2017) Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. Bioorg.Med.Chem. **25** 3098. PMID: 28433511.